Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Published byGarey Todd Modified over 5 years ago

Similar presentations

Presentation on theme: "Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed."— Presentation transcript:

1 Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed in 1961–1984 (group A) and 1985–1999 (group B), by years of observation. Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed in 1961–1984 (group A) and 1985–1999 (group B), by years of observation. The cumulative incidences of ESRD were plotted according to (E) duration of T1DM and (F) post-pubertal duration. ESRD, end-stage renal disease; T1DM, type 1 diabetes mellitus. Toshika Otani et al. BMJ Open Diab Res Care 2016;4:e000177 ©2016 by American Diabetes Association

Download ppt "Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed."

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p
Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.

Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.
Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)
Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.

Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),

Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Similar presentations

Ads by Google